Harmony Biosciences
Update in progressHRMY (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on rare neurological diseases in the United States. It markets WAKIX (pitolisant) for excessive daytime sleepiness in adults with narcolepsy and develops multiple programs, including BP1.15205 (orexin 2 receptor agonist), HBS-102 (MCHR1 antagonist), and ZYN-002 for Fragile X and 22q Deletion. It also advances EPX-100, EPX-200, CBS105, and CBS104, plus other earlier-stage products. Formerly Harmony Biosciences II, it changed its name in 2020. Founded in 2017, it is headquartered in Plymouth Meeting, Pennsylvania.
Company score
- Sentiment
- -0.03
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.02
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.02
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!